Molecular imaging with trastuzumab and pertuzumab of HER2-positive breast cancer in mice: a step towards personalized medicine

被引：0
|
作者：
Collin, B.
Oudot, A.
Vrigneaud, J-M
Moreau, M.
Raguin
Duchamp
Tizon, X.
Denat, F.
Varoqueaux, N.
Brunotte, F.
Fumoleau, P.
机构：
[1] Ctr Georges Francois Leclerc, Dijon, France
[2] Univ Bourgogne, Inst Chim Mol, Dijon, France
[3] Oncodesign, Dijon, France
[4] Roche, Boulogne Billancourt, France
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P4-02-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-06
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [2] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    [J]. ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [3] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [4] Preclinical Evaluation of Indium 111 Radiolabeled Trastuzumab and Pertuzumab for HER2-positive Breast Cancer Molecular Imaging
    Oudot, A.
    Collin, B.
    Raguin, O.
    Moreau, M.
    Vrigneaud, J. M.
    Duchamp, O.
    Varoqueaux, N.
    Denat, F.
    Brunotte, F.
    Fumoleau, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 161 - 161
  • [5] Personalized Medicine in HER2-positive breast cancer
    Tsurutani, Junji
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Personalized medicine for HER2-positive breast cancer
    Wang, Zhixiang
    [J]. BREAST CANCER MANAGEMENT, 2015, 4 (05) : 237 - 240
  • [7] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [8] Pertuzumab: a step forward in treating HER2-positive breast cancer
    Mavroudis, Dimitrios
    [J]. TRANSLATIONAL CANCER RESEARCH, 2012, 1 (02) : 117 - 118
  • [9] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
  • [10] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    [J]. JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
12345